TY - JOUR
T1 - Platelet activation and vascular endothelial growth factor 165 release in hepatocellular cancer
AU - Ferroni, Patrizia
AU - Spila, Antonella
AU - D'Alessandro, Roberta
AU - Martini, Francesca
AU - Iacovone, Francesca
AU - Ettorre, Giuseppe M.
AU - Vennarecci, Giovanni
AU - Santoro, Roberto
AU - Puoti, Claudio
AU - Guadagni, Fiorella
PY - 2011/2/20
Y1 - 2011/2/20
N2 - Background: Vascular endothelial growth factor (VEGF165) is stored, transported and released by platelets. Platelet functional abnormalities have been described in patients with hepatocellular carcinoma (HCC). Thus, this study was designed to investigate the behavior of VEGF165 with respect to platelet activation in HCC. Methods: Plasma and serum VEGF165 and plasma sP-selectin levels were analyzed in patients with HCC (n=70) or cirrhosis (n=45) and control subjects (n=70). Given the thrombocytopenia that characterizes both HCC and cirrhotic patients, plasma VEGF165 and sP-selectin as well as serum VEGF (plt-VEGF165-load) levels were normalized by platelet counts. Results: Median concentrations of plasma VEGF165/platelet (p=0.002) and sP-selectin/platelet (p165/platelet at multivariate analysis (p165-load correlated with tumor diameter (p165 release by tumor in HCC. It is plt-VEGF165-load, but not plasma VEGF165 or serum VEGF165 that is an independent predictor for overall survival of HCC patients.
AB - Background: Vascular endothelial growth factor (VEGF165) is stored, transported and released by platelets. Platelet functional abnormalities have been described in patients with hepatocellular carcinoma (HCC). Thus, this study was designed to investigate the behavior of VEGF165 with respect to platelet activation in HCC. Methods: Plasma and serum VEGF165 and plasma sP-selectin levels were analyzed in patients with HCC (n=70) or cirrhosis (n=45) and control subjects (n=70). Given the thrombocytopenia that characterizes both HCC and cirrhotic patients, plasma VEGF165 and sP-selectin as well as serum VEGF (plt-VEGF165-load) levels were normalized by platelet counts. Results: Median concentrations of plasma VEGF165/platelet (p=0.002) and sP-selectin/platelet (p165/platelet at multivariate analysis (p165-load correlated with tumor diameter (p165 release by tumor in HCC. It is plt-VEGF165-load, but not plasma VEGF165 or serum VEGF165 that is an independent predictor for overall survival of HCC patients.
KW - Angiogenesis
KW - Hepatocellular carcinoma
KW - Platelet activation
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=78650907073&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650907073&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2010.11.026
DO - 10.1016/j.cca.2010.11.026
M3 - Article
C2 - 21111726
AN - SCOPUS:78650907073
VL - 412
SP - 450
EP - 454
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
SN - 0009-8981
IS - 5-6
ER -